Publications by authors named "Aanya Bahl"
Article Synopsis
- Blood-based biomarkers may help diagnose Alzheimer's Disease (AD), but previous studies haven't fully explored their effectiveness in diverse community groups.
- The study analyzed 546 older adults from a multi-ethnic urban cohort, measuring biomarkers like phosphorylated-tau-181 and amyloid-beta to identify their association with AD and cognitive impairment.
- Key findings showed some biomarkers correlated with clinical AD diagnoses, but sensitivity and specificity levels were moderate, suggesting that factors like education and comorbidities may affect biomarker reliability.
Background: Alzheimer's disease (AD) biomarkers can help differentiate cognitively unimpaired (CU) individuals from mild cognitive impairment (MCI) and dementia. The role of AD biomarkers in predicting cognitive impairment and AD needs examination.
Methods: In 628 CU individuals from a multi-ethnic cohort, amyloid beta (Aβ)42, Aβ40, phosphorylated tau-181 (p-tau181), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL) were measured in plasma.
Introduction: Alzheimer's disease (AD) biomarkers can help differentiate cognitively unimpaired (CU) individuals from mild cognitive impairment (MCI) and dementia. The role of AD biomarkers in predicting cognitive impairment and AD needs examination.
Methods: In 628 CU individuals from a multi-ethnic cohort, Aβ42, Aβ40, phosphorylated tau-181 (P-tau181), glial fibrillary acid protein (GFAP), and neurofilament light chain (NfL) were measured in plasma.